Eur Rev Med Pharmacol Sci 2023; 27 (7): 2715-2715
DOI: 10.26355/eurrev_202304_31896

Author Correction: An investigation into the mechanism of nobiletin’s inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology

Q.-J. Du, Q. Li, R.-H. Zhou, H. Wang, Q. Yan, W.-J. Dang, J.-J. Guo

Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.


Correction to: European Review for Medical and Pharmacological Sciences 2023; 27 (4): 1553-1564. DOI: 10.26355/eurrev_202302_31398-PMID: 36876711-published online on February 15, 2023.

 

After publication, the authors applied some corrections to the galley proof:

–       The order of Table I and II has been inverted.

–       The scale bar of Figure 9A has been inserted in the Legend.

 

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.

An investigation into the mechanism of nobiletin’s inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology

Free PDF Download

To cite this article

Q.-J. Du, Q. Li, R.-H. Zhou, H. Wang, Q. Yan, W.-J. Dang, J.-J. Guo
Author Correction: An investigation into the mechanism of nobiletin’s inhibition of papillary thyroid cancer using network pharmacology analysis and experimental pharmacology

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 7
Pages: 2715-2715
DOI: 10.26355/eurrev_202304_31896